Indaptus Therapeutics (INDP) director Jerome Jabbour files initial Form 3

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. filed an initial insider ownership report for board member Jerome D. Jabbour on Form 3. This filing establishes his status as a director subject to insider reporting rules. The report does not list any buy, sell, or other share transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jabbour Jerome D

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC.

3 COLUMBUS CIRCLE 15TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/26/2026

3. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The Reporting Person does not beneficially own any securities of the company.

No securities are beneficially owned.

	/s/ Jerome Jabbour	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Indaptus Therapeutics (INDP) Form 3 filing report for Jerome D. Jabbour?

The Form 3 for Indaptus Therapeutics director Jerome D. Jabbour reports his initial insider ownership status. It confirms he is a board member subject to SEC insider reporting rules, but it does not disclose any specific stock transactions or share amounts.

Does the Indaptus Therapeutics (INDP) Form 3 show any insider buying or selling?

No, the Indaptus Therapeutics Form 3 for Jerome D. Jabbour shows no insider buying or selling. The transaction summary lists zero buy, sell, acquire, or dispose events, indicating this filing is purely an initial ownership report, not a record of trades.

Who is the reporting person on the Indaptus Therapeutics (INDP) Form 3?

The reporting person is Jerome D. Jabbour, identified as a director of Indaptus Therapeutics, Inc. The filing confirms his role as a board member subject to insider reporting obligations, without indicating he is an officer or a ten percent beneficial owner.

Why is this Form 3 for Indaptus Therapeutics (INDP) important to investors?

This Form 3 matters because it formally identifies Jerome D. Jabbour as an insider director at Indaptus Therapeutics. Once disclosed, future Forms 4 and 5 can be tracked against this baseline, helping investors monitor any later share transactions he may report.

Does the Indaptus Therapeutics (INDP) Form 3 include any special footnote disclosures?

The Form 3 data includes a placeholder for footnotes but no substantive entries. That means there are no additional disclosed details about indirect holdings, voting or investment control limitations, or ownership through entities beyond what is already reflected in the core fields.